NasdaqGM - Nasdaq Real Time Price USD

Iovance Biotherapeutics, Inc. (IOVA)

1.6600
-0.1000
(-5.68%)
At close: May 16 at 4:00:01 PM EDT
1.6300
-0.03
(-1.81%)
Pre-Market: 8:58:06 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
212,679
164,070
1,189
0
0
Cost of Revenue
166,475
123,995
10,755
0
0
Gross Profit
46,204
40,075
-9,566
0
0
Operating Expense
444,981
435,353
450,993
398,878
342,703
Operating Income
-398,777
-395,278
-460,559
-398,878
-342,703
Net Non Operating Interest Income Expense
20,155
20,273
13,043
2,985
451
Pretax Income
-378,622
-375,005
-447,516
-395,893
-342,252
Tax Provision
-3,258
-2,828
-3,479
0
0
Net Income Common Stockholders
-375,364
-372,177
-444,037
-395,893
-342,252
Diluted NI Available to Com Stockholders
-375,364
-372,177
-444,037
-395,893
-342,252
Basic EPS
-1.22
-1.28
-1.89
-2.49
-2.23
Diluted EPS
-1.22
-1.28
-1.89
-2.49
-2.23
Basic Average Shares
304,039
289,877
235,131
159,259
153,406
Diluted Average Shares
304,039
289,877
235,131
159,259
153,406
Total Operating Income as Reported
-398,777
-395,278
-460,559
-398,878
-342,703
Total Expenses
611,456
559,348
461,748
398,878
342,703
Net Income from Continuing & Discontinued Operation
-375,364
-372,177
-444,037
-395,893
-342,252
Normalized Income
-375,364
-372,177
-444,037
-395,893
-342,252
Interest Income
20,155
20,273
13,043
2,985
451
Net Interest Income
20,155
20,273
13,043
2,985
451
EBIT
-398,777
-395,278
-460,559
-398,878
-342,703
EBITDA
-354,013
-351,672
-427,432
-377,743
-328,723
Reconciled Cost of Revenue
166,475
123,995
10,755
0
0
Reconciled Depreciation
44,764
43,606
33,127
21,135
13,980
Net Income from Continuing Operation Net Minority Interest
-375,364
-372,177
-444,037
-395,893
-342,252
Normalized EBITDA
-354,013
-351,672
-427,432
-377,743
-328,723
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 10/15/2010

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VKTX Viking Therapeutics, Inc.
28.43
+3.76%
 
AXSM Axsome Therapeutics, Inc.
107.53
+0.29%
 
IBRX ImmunityBio, Inc.
2.8400
+6.37%
 
SRPT Sarepta Therapeutics, Inc.
36.43
+3.29%
 
TGTX TG Therapeutics, Inc.
34.36
+2.29%
 
MDGL Madrigal Pharmaceuticals, Inc.
290.96
-0.29%
 
SMMT Summit Therapeutics Inc.
23.87
+3.38%
 
ALT Altimmune, Inc.
5.58
-3.46%
 
BLUE bluebird bio, Inc.
4.9700
0.00%
 
NTLA Intellia Therapeutics, Inc.
8.50
+5.26%